Calliditas wins the 2020 SwedenBio Award
The winner of this year’s SwedenBIO Award was announced on Wednesday December 9[th]. Calliditas Therapeutics AB (publ) (“Calliditas”) received the award in recognition of its successful clinical development program of Nefecon, which culminated in the recent positive topline data readout of the pivotal Phase 3 NefIgArd trial.SwedenBio annually awards this prize to a company which has excelled in terms of R&D, business development and growth whilst contributing to societal benefit. “This year’s winner has shown impressive professionalism and staying power with regards to the development of